Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.64 |
| ▸ | SRC | P12931 | 5/20 | 0.63 |
| ▸ | ABL1 | P00519 | 4/20 | 0.61 |
| ▸ | BRAF | P15056 | 5/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21479378 | 0.96 | KIT (0.60) | KITSRCABL1BRAFNR1H2 | |
| SCHEMBL12516824 | 0.91 | RET (0.62) | KITSRCABL1BRAFEGFR | |
| SCHEMBL20912769 | 0.88 | KIT (0.71) | KITSRCABL1BRAFNR1H2 | |
| SCHEMBL31053459 | 0.88 | KIT (0.66) | KITSRCABL1BRAFNR1H2 | |
| SCHEMBL14704590 | 0.88 | KIT (0.66) | KITSRCABL1BRAFNR1H2 | |
| SCHEMBL30904911 | 0.88 | KIT (0.71) | KITSRCABL1BRAFNR1H2 | |
| SCHEMBL21479383 | 0.88 | SRC (0.65) | KITSRCABL1BRAFEGFR | |
| SCHEMBL20227773 | 0.87 | KIT (0.65) | KITSRCABL1BRAFNR1H2 | |
| SCHEMBL4933270 | 0.87 | KIT (0.65) | KITSRCABL1BRAFNR1H2 | |
| SCHEMBL19986829 | 0.87 | KIT (0.68) | KITSRCABL1BRAFNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | PURDUE RESEARCH FOUNDATION | 2021-06-22 | — | — | US | disclosed |
| US-10870647-B2 | Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-12-22 | — | — | US | disclosed |
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2020-10-01 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20190315738-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2019-10-17 | — | — | US | disclosed |
| US-8987275-B2 | Indazole compounds and their uses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2011090738-A2 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | KDM1B, JMJD6, KDM1A | KIT 1444/4885SRC 271/4885ABL1 79/4885 |
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | KIT 3392/4885SRC 296/4885ABL1 85/4885 |
| US-20190315738-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | FYN, SRC, LCK | KIT 268/4885SRC 2/4885ABL1 57/4885 |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | KDM1B, JMJD6, KDM1A | KIT 1444/4885SRC 271/4885ABL1 79/4885 |
| US-10870647-B2 | Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer | FYN, SRC, LCK | KIT 193/4885SRC 2/4885ABL1 49/4885 |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KIT 3392/4885SRC 296/4885ABL1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.